The premium beauty brand’s growth plans include US expansion, a myth-busting global skin care campaign and bigger investment in R&D
Medik8’s growth plans include US expansion and a new jargon-busting beauty campaign
Although already well established in regions like the UK and Europe, the brand’s next phase of expansion involves upping the ante in the US and investing heavily in R&D.
As well as launching a new global educational consumer skin care campaign.
To make these goals a reality, the cosmeceutical company has undergone some big changes, including appointing beauty leadership veteran Simon Coble its new CEO.
The science-based skin ageing products company also moved into a “bigger and better” Innovation Centre in Buckinghamshire, UK, in September 2022 in a bid to scale up production output.
It now runs full end-to-end capability – from conception to completion – within a 25-mile radius.
It is important that we double down to ensure that we educate our consumers about the Medik8 difference – Medik8 CEO Simon Coble
In just 11 months Medik8 has also doubled its research and development investment and plans to quadruple the facility’s capacity by the end of 2024.
“We live in a complex world, particularly in terms of beauty messaging, so I think Medik8’s simple skin care philosophy of CSA [vitamin C and sunscreen use in the morning, followed by vitamin A at night] is a really unique point for us,” says Coble.
“We also make the majority of our product in-house and will get to a point shortly where we make all of it this way.
“Where we own every step of the process, from ideation to manufacture, whereas...
This is a small extract of the full article which is available ONLY to premium content subscribers. Subscribers sign-in (top right) to read the article.
Subscribe now to premium content on Cosmetics Business